Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition

The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1(+) T-cells and acts on antigen-specific stem-like PD-1(+) TCF-1(+) CD8(+) T-cells expanding and differentiating them towards better effectors resulting in sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Codarri Deak, Laura, Hashimoto, Masao, Umaña, Pablo, Klein, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072055/
https://www.ncbi.nlm.nih.gov/pubmed/37025392
http://dx.doi.org/10.1080/2162402X.2023.2197360
_version_ 1785019309925335040
author Codarri Deak, Laura
Hashimoto, Masao
Umaña, Pablo
Klein, Christian
author_facet Codarri Deak, Laura
Hashimoto, Masao
Umaña, Pablo
Klein, Christian
author_sort Codarri Deak, Laura
collection PubMed
description The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1(+) T-cells and acts on antigen-specific stem-like PD-1(+) TCF-1(+) CD8(+) T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition.
format Online
Article
Text
id pubmed-10072055
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-100720552023-04-05 Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition Codarri Deak, Laura Hashimoto, Masao Umaña, Pablo Klein, Christian Oncoimmunology Author’s View The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1(+) T-cells and acts on antigen-specific stem-like PD-1(+) TCF-1(+) CD8(+) T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition. Taylor & Francis 2023-03-30 /pmc/articles/PMC10072055/ /pubmed/37025392 http://dx.doi.org/10.1080/2162402X.2023.2197360 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Author’s View
Codarri Deak, Laura
Hashimoto, Masao
Umaña, Pablo
Klein, Christian
Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
title Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
title_full Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
title_fullStr Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
title_full_unstemmed Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
title_short Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
title_sort beyond checkpoint inhibition: pd-1 cis-targeting of an il-2rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072055/
https://www.ncbi.nlm.nih.gov/pubmed/37025392
http://dx.doi.org/10.1080/2162402X.2023.2197360
work_keys_str_mv AT codarrideaklaura beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition
AT hashimotomasao beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition
AT umanapablo beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition
AT kleinchristian beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition

Ejemplares similares